Semaglutide

Product

GLP-1 receptor agonist medication sold as Ozempic and Wegovy by Novo Nordisk

4 stories

Scientists Identify Biological Mechanism Behind Why Ozempic Fails for Some Patients

FDA Approves Eli Lilly's Oral Weight-Loss Drug, Entering Market Against Novo Nordisk

Eli Lilly's Obesity Drug Retatrutide Succeeds in Late-Stage Diabetes Trial

Two Deaths Reported to Regulators Potentially Linked to Weight-Loss Injections